We compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive regimens.
INTRODUCTION
Most trials of first-line chemotherapy for advanced breast cancer have tested whether intensive regimens improve outcomes in women fit enough to tolerate them. However, intensive regimens may be unsuitable for many women with advanced breast cancer (eg, those who are older; who have significant comorbidities; and perhaps whose disease is indolent, of low volume, and/or bone dominant). Intensive regimens may also be unsuitable for women who want to minimize treatment toxicity (eg, those who relapse after intensive regimens of adjuvant chemotherapy). Few trials have focused on this important and substantial subgroup unsuited for intensive first-line chemotherapy.
Capecitabine is an oral prodrug that is converted to fluorouracil by an enzymatic pathway ending with thymidine phosphorylase, which is present at higher levels in sensitive tumor cells than in normal cells. Capecitabine showed significant activity with an objective tumor response rate of 20% in a single-arm trial of women with heavily pretreated breast cancer. 1 Small randomized trials in advanced breast cancer have suggested that capecitabine has comparable activity to paclitaxel and intravenous CMF administered every 3 weeks. 2, 3 However, classical CMF is substantially more effective than this every-3-week intravenous regimen. 4 A continuous regimen of capecitabine at 666 mg/m 2 twice daily had similar activity and
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less toxicity than an intermittent regimen of 1,250 mg/m 2 twice daily for 14 of every 21 days in advanced colorectal cancer. 5 The duration of chemotherapy seems important in advanced breast cancer. We previously showed that continuing chemotherapy until progression was superior to administering it for three cycles, then stopping and administering an additional three cycles at each sign of progression. 6 A meta-analysis of randomized trials showed that administering chemotherapy for a longer duration resulted in better survival than administering the same chemotherapy for a shorter duration. 7 Capecitabine provides a convenient way of administering chemotherapy over a protracted period. Oral chemotherapy was attractive to many patients surveyed with a range of advanced cancers. 8 The aim of this trial was to determine whether treatment with capecitabine was preferable to that with classical CMF and whether capecitabine administered continuously (21 of every 21 days) was preferable to the same total dose administered intermittently (14 of every 21 days) in women with advanced breast cancer unsuited to more intensive first-line chemotherapy. We hypothesized that quality-adjusted progression-free survival (PFS) would be better with capecitabine than with classical CMF and with continuous rather than intermittent capecitabine, through a combination of equivalent or better tumor control, equivalent or lesser toxicity, and greater patient acceptability.
PATIENTS AND METHODS

Patients
The protocol described the target population as women with "advanced breast cancer where chemotherapy for advanced disease is being considered for the first time, and where more intensive chemotherapy is not considered more appropriate," without further specification. Key eligibility criteria included a pathologic diagnosis of breast cancer, suitability for chemotherapy with either CMF or capecitabine, performance status (PS; Eastern Cooperative Oncology Group [ECOG]) of 0 to 3, neutrophil count of 1.5 ϫ 10 9 /L or greater, platelet count of 75 ϫ 10 9 /L or greater, calculated creatinine clearance of 30 mL/min or greater, and serum bilirubin less than 50 mol/L. Measurable disease was not required. Key exclusion criteria were previous chemotherapy for advanced breast cancer, adjuvant chemotherapy within the last 6 months, an indication for chemotherapy more intensive than CMF or capecitabine, and GI disease precluding oral chemotherapy. All patients provided signed, written informed consent. The protocol was approved by the human research ethics review committees at all participating institutions.
Random assignment was performed centrally by telephone and balanced dynamically for treating institution, ECOG PS (0 to 1 v 2 to 3), presence of liver and/or brain metastases, planned use of bisphosphonates, and planned use of prednisone with CMF.
9 Participants were randomly assigned to intermittent capecitabine, continuous capecitabine, or the classical Bonadonna regimen of oral cyclophosphamide with intravenous methotrexate and fluorouracil (ie, CMF).
Treatments
Intermittent capecitabine was started at 1,000 mg/m 2 twice daily on days 1 through 14 and repeated every 3 weeks. The dose was increased to 1,250 mg/m 2 twice daily in the absence of adverse events after two cycles. Continuous capecitabine was started at 650 mg/m 2 twice daily on days 1 through 21 and repeated every 3 weeks with no dose escalation. CMF consisted of oral cyclophosphamide 100 mg/m 2 on days 1 through 14, with methotrexate 40 mg/m 2 and fluorouracil 600 mg/m 2 administered intravenously on days 1 and 8 and repeated every 4 weeks. Methotrexate doses were reduced for patients with a calculated creatinine clearance of 30 to 70 mL/min. Prednisolone 40 mg/m 2 /d on days 1 through 14 was permitted with CMF. Doses were based on surface area calculated with the lesser of ideal or actual body weight. Treatment was delayed until toxicities other than alopecia had resolved to grade 1 or lower. Dose reductions of approximately 25% were recommended for prespecified toxicities. Concurrent treatment with trastuzumab was not allowed. Treatment was to continue until disease progression, patient intolerance, or unacceptable toxicity without any specified maximum duration. Management after disease progression was at the supervising clinicians' discretion. Use of subsequent chemotherapy was recorded, but its dose, duration, and outcome were not.
Assessments
Patients were assessed and completed quality-of-life assessments before each cycle of chemotherapy: every 3 weeks for those receiving capecitabine and 4 weeks for CMF. Adverse events were rated with the National Cancer Institute Common Toxicity Criteria, version 2.0.
10 Computerized axial tomographic scans of the chest and abdomen and skeletal radionucleide scans were performed at baseline and every 12 weeks until progression. Quality-of-life assessments were completed every 4 weeks from treatment cessation to progression.
The primary outcome was quality-adjusted PFS. Secondary outcomes included PFS (from random assignment to progression or death), overall survival (OS; random assignment to death), and objective tumor response (complete plus partial response). The need for palliative radiation or change in chemotherapy was taken to indicate disease progression. Objective tumor response was assessed according to RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 and required confirmatory imaging at least 1 month after initial documentation.
11
Statistical Considerations
The planned sample size of 465 patients (155 per arm) accrued over 3 years and observed for 1 additional year was designed to give 80% power to detect a 36% improvement in median PFS from 6 to 8.15 months (hazard ratio [HR], 0.74) comparing the combined capecitabine groups with the CMF group. Recruitment was stopped by the trial management committee after 325 patients had been accrued over 4 years because of diminishing support, without knowledge of any efficacy results.
Planned comparisons for each end point were performed in two steps. The two capecitabine groups were compared first, and if the P value was greater than .05, they were combined for a definitive comparison with the CMF group. If comparison of the two capecitabine groups yielded a P value of .05 or less, then the definitive analysis for that end point was to be of the three separate groups. KaplanMeier curves for PFS and OS were constructed and compared using the log-rank testfortheprimaryanalysesoftime-to-eventdata.Theinfluenceofbaselinefactors on treatment effects was assessed by testing for interactions with treatment in Cox proportional hazards models for PFS and OS. All analyses were by intention to treat. All P values and CIs are two sided.
Quality adjusted PFS for each group was the product of its mean utility score and the area under its time-to-progression curve truncated at 36 months.
12 Utility scores from random assignment to progression were calculated and combined for each treatment group.
13,14 CIs and P values for differences between groups were calculated with bootstrap methods. Detailed descriptions of the quality-of-life instruments, data, analyses, and results will be published separately.
RESULTS
We recruited 325 women from 34 centers between July 2001 and June 2005 (Fig 1) . Two were judged ineligible and excluded from the primary analyses: one assigned continuous capecitabine had her diagnosis changed from metastatic breast cancer to non-small-cell lung cancer after random assignment but before start of treatment; the other assigned intermittent capecitabine was administered trastuzumab concurrently. All reported analyses are based on 323 eligible women with a median follow-up of 3.3 years. Inclusion of the ineligible women did not materially alter the results or conclusions.
Baseline characteristics were well balanced among the three treatment groups (Table 1 ). The median age was 62 years; 23% were age 70 years or older, and 25% were age 55 years or younger. Almost half of the women had liver and/or brain metastases, and 13% had poor PS (ECOG 2 or 3). Approximately one third had received adjuvant chemotherapy at least 6 months previously, mostly with CMF.
Approximately two thirds had hormone receptor-positive tumors, all of whom had undergone previous endocrine therapy.
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Progressive disease was documented in 296 (92%) of the 323 women. PFS was similar in those assigned capecitabine intermittently versus continuously (median, 6 months; HR, 0.97; 95% CI, 0.73 to 1.28; P ϭ .8) and in those assigned capecitabine versus CMF (median, 6 months; HR, 0.86; 95% CI, 0.67 to 1.10; P ϭ .20; Fig 2A) . Poor PS was the only baseline factor significantly associated with PFS, and adjustment for it in a multivariable Cox model did not affect the size or statistical significance of the effect of treatment on PFS (Table 3) . Quality-adjusted PFS, the primary end point for the trial, was similar in those assigned capecitabine versus CMF (mean, 8.8 v 7.6 months; 95% CI for difference, Ϫ0.75 to 3.0; P ϭ .20).
OS analyses included 237 deaths (73%) among the 323 women. OS was similar in those assigned capecitabine intermittently versus continuously (HR, 0.86; 95% CI, 0.62 to 1.12; P ϭ .4). OS was substantially longer in those assigned capecitabine versus CMF (median, 22 v 18 months; HR, 0.72; 95% CI, 0.55 to 0.94; P ϭ .02; Fig 2B) . Longer survival was also associated with presence of hormone receptors, good PS, and absence of liver or brain metastases (Table 3) . Adjustment for these baseline factors did not materially alter the size or statistical significance of the survival benefit associated with capecitabine. Weak interaction effects reflected somewhat greater survival benefits for capecitabine over CMF in the absence of previous adjuvant chemotherapy (P ϭ .07) or with a longer interval from diagnosis to treatment (P ϭ .10).
Adverse events occurred equally frequently in those assigned capecitabine intermittently or continuously (Table 4) . Hand-foot syndrome was more frequent with capecitabine, whereas uncomplicated neutropenia, febrile neutropenia, stomatitis, and miscellaneous other grade 3 or 4 adverse events were more frequent with CMF. Serious adverse events occurred in significantly fewer patients assigned capecitabine than CMF (21% v 35%; P ϭ .02), particularly those related to neutropenia (Table 5) .
Dose reductions were equally frequent with capecitabine administered intermittently and continuously. The dose of capecitabine was reduced by one level (to 75% of starting dose) in 82 (38%) of 214 women and by two levels (to 50% of starting dose) in another 33 women (15%). Dose escalation of intermittent capecitabine (from 1,000 mg/m 2 twice daily to 1,250 mg/m 2 twice daily) was attempted in 11 (10%) of 107 women, six of whom experienced an adverse event requiring a dose reduction within two cycles.
The average duration of chemotherapy was longer in those assigned capecitabine than in those assigned CMF (9 months, 12.1 cycles v 6 months, 5.5 cycles; Appendix Table A1 , online only). Women assigned capecitabine rather than CMF were more likely to continue chemotherapy beyond 6 months (40% v 21%; P ϭ .001) and beyond 12 months (18% v 6%; P ϭ .005). Chemotherapy was continued until progression in significantly more women allocated capecitabine than CMF (77% v 51%; P Ͻ .001; Appendix Table A2 , online only). A posthoc exploratory analysis with a time-dependent Cox model was performed to assess the effects of treatment on PFS during the first 6 months separately from the effects beyond 6 months. During the first 6 months, PFS was similar in those assigned capecitabine or CMF (HR, 1.15; 95% CI, 0.82 to 1.63; P ϭ .4); beyond 6 months, PFS was significantly longer in those assigned capecitabine (HR, 0.62; 95% CI, 0.44 to 0.88; P ϭ .007).
Most women (91%) received second or subsequent lines of chemotherapy, including capecitabine in approximately one third of women originally assigned CMF and CMF in approximately one eighth of women originally assigned capecitabine (Appendix Table  A3 , online only). Other cytotoxic drugs and trastuzumab were used similarly often after progression in the three treatment groups. The effects and duration of second and subsequent lines of chemotherapy Abbreviations: AC, doxorubicin and cyclophosphamide; BC, breast cancer; CMF, cyclophosphamide, methotrexate, and fluorouracil; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor. were not collected. The estimated benefit of capecitabine on OS was unaffected by subsequent use of trastuzumab (interaction P ϭ 0.3).
DISCUSSION
OS was significantly longer with capecitabine than CMF, despite similar rates of objective tumor response, disease control, PFS over the first 6 months, and quality-adjusted PFS. Capecitabine was better tolerated than CMF and less likely to be stopped for reasons other than progression, resulting in longer treatment continuation, better PFS beyond 6 months, and better OS beyond 12 months. The effects of capecitabine, both beneficial and adverse, were similar whether the same total dose was administered intermittently or continuously. We chose quality-adjusted PFS as the primary end point and PFS as the primary measure of efficacy because of concerns that subsequent chemotherapy would obscure any effects on OS. However, OS is the most direct, reliable, and compelling measure of patient benefit. OS and PFS, with both capecitabine and CMF, were similar or better in this trial than in comparable contemporary trials.
15 This is probably because of both the nature of our study population and the efficacy of our treatments (assigned and subsequent).
Wespeculatethatlongertreatmentdurationwithcapecitabinecompared with CMF caused the observed improvements in OS and PFS beyond 6 months without an effect on objective tumor response. The larger improvement in OS compared with PFS raises the possibility that subsequent chemotherapy was more effective after capecitabine than after CMF. This might have occurred if there was less tumor resistance induced by exposure to one drug rather than three or if subsequent chemotherapy was more deliverable after capecitabine because it caused less cumulative bone marrow dysfunction than CMF.
The possible importance of chemotherapy duration is highlighted by apparently contradictory results from a trial of capecitabine versus CMF or doxorubicin and cyclophosphamide (AC) as adjuvant chemotherapy for women age 65 years or older with early breast cancer (CALGB [Cancer and Leukemia Group B] 49907). 16 In that trial, relapse-free survival and OS were significantly shorter in women assigned capecitabine. The CALGB trial had a larger sample size than our trial (600 v 325 participants) but fewer relapses (95 v 296) and deaths (62 v 237). The different age ranges and stages of disease do not explain the divergent results. Similar doses of capecitabine and CMF and identical average durations of CMF (6 months) were used in both trials. Use of AC in 56% of the control group of the adjuvant trial is unlikely to have affected the results, because four cycles of AC administered every 3 weeks has produced results similar to those with six cycles of classical CMF in the adjuvant setting.
17, 18 The average duration of treatment with capecitabine was the most notable difference: 18 weeks in the adjuvant trial versus 36 weeks in our trial. The results of our trial should not be extrapolated to the adjuvant setting.
We started intermittent capecitabine at a dose of 1,000 mg/m 2 twice daily, 20% lower than the recommended starting dose, and 50% of women had dose reductions for toxicity, yet objective tumor response rates, PFS, and OS were similar or better than those with CMF. This suggests that even substantial dose reductions do not adversely affect the anticancer activity of capecitabine and may contribute to the improved tolerability we observed. Other studies using doses of capecitabine lower than those recommended have reached similar conclusions. 19 These data raise the hypothesis that starting capecitabine at a dose lower than 1,250 mg/m 2 twice per day may be preferable; a randomized trial comparing starting doses is needed for a definitive answer to this question.
The main strengths of our trial were its inclusive eligibility criteria, consistency of results across subgroups, and extended follow-up. The relative effects of capecitabine versus CMF were similar in all relevant clinical subgroups. Extended follow-up resulted in events being observed in the majority of participants, giving the trial sufficient power to detect moderate treatment effects, despite stopping early. Posthoc power calculations show the trial as conducted provided 66% power to detect the PFS effect specified by the protocol.
The main limitations of our trial are the ambiguity of broad, pragmatic eligibility criteria and the use of an unfashionable control regimen. We chose to include the large and heterogeneous subset of women with advanced breast cancer for whom more intense first-line chemotherapy was considered unsuitable. Although it is difficult to define this population precisely, we believe it is an easily identified and substantial proportion of women encountered in routine clinical practice but poorly represented in clinical trials. Our choice in 2000 of classical CMF as the comparator is open to criticism, because it is no longer regarded as a standard of care and may be considered a suboptimal control. However, other regimens that might be considered standard in this setting (eg, AC, single-agent anthracycline, or single-agent taxane) have comparable efficacy. 6, [20] [21] [22] Furthermore, many women now present with metastatic disease after adjuvant therapy that included an anthracycline and/or taxane. The proportion of patients treated with trastuzumab after progressionwassimilarinthecapecitabineandCMFgroupsanddidnotaffectthe estimated treatment effect.
More intensive regimens may be preferable for women with extensive, rapidly progressing, or life-threatening visceral disease. [23] [24] [25] [26] [27] [28] However, these regimens are also more toxic and may be less suitable for women with advanced breast cancer who have significant comorbidities, have had bad experiences with adjuvant chemotherapy, or have breast cancer that is indolent or of low volume and are considering a less intense first-line regimen. Abbreviations: CMF, cyclophosphamide, methotrexate, and fluorouracil; SAE, serious adverse event. 
